Rite Aid Corp upgraded its estimates for the adjusted EBITDA for the year 2022 and forecasts a reduction of losses per share, while it also downgraded the estimates for the income.
The healthcare and retail services company downgraded its revenue estimates for the year 2022 between $ 24.4-24.7 billion.
Revenue from the pharmaceutical services sector is expected to reach $ 7.1-7.2 billion.
In September, the company expected total revenue of $ 25.1-25.5 billion and revenue from the pharmaceutical department of $ 7.7-7.8 billion.
Convergent estimates for 2022 sales speak of $ 25 billion.
The forecast for the adjusted EBITDA speaks of 500-520 million dollars, higher than the September estimates for 460-500 million dollars.
The company forecasts a reduction in adjusted losses per share to 49 cents, compared to September estimates for adjusted losses of 90-53 five.
Convergent estimates point to adjusted losses of 77 cents.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
